Financial Performance - For the year ending December 31, 2025, the group's revenue from continuing operations increased by approximately 0.80% to approximately RMB 859 million, compared to RMB 852 million in 2024[2]. - The gross profit for the year ending December 31, 2025, was approximately RMB 143 million, down from RMB 169 million in 2024, resulting in a gross margin of approximately 16.69%, compared to 19.79% in 2024[2][4]. - The group reported a loss of approximately RMB 265 million for the year ending December 31, 2025, compared to a profit of approximately RMB 34 million in 2024[2][4]. - Basic and diluted loss per share from continuing operations was approximately RMB 14.41 for the year ending December 31, 2025, compared to RMB 8.54 in 2024[4]. - Total comprehensive loss for the year was approximately RMB 27.3 million, compared to a comprehensive income of RMB 0.53 million in 2024[5]. - Reported revenue from external customers for 2025 was RMB 85,900,000, a decrease of 5.6% from RMB 90,938,000 in 2024[27]. - Adjusted EBITDA for 2025 was a loss of RMB 7,261,000 compared to a profit of RMB 4,385,000 in 2024[27]. - Total comprehensive loss before tax for continuing and discontinued operations was RMB 26,997,000 in 2025, down from a profit of RMB 4,544,000 in 2024[27]. - The company reported a loss attributable to owners of RMB 22,040,000, compared to a profit of RMB 4,892,000 for the previous year[36]. - The company reported a substantial decrease in contract liabilities from RMB 4,147,000 in 2024 to RMB 588,000 in 2025[50]. Assets and Liabilities - Non-current assets decreased to approximately RMB 78 million as of December 31, 2025, from RMB 103 million in 2024[6]. - Current assets decreased to approximately RMB 344 million as of December 31, 2025, compared to RMB 366 million in 2024[6]. - The group's net assets decreased to approximately RMB 324 million as of December 31, 2025, from RMB 352 million in 2024[7]. - The group’s cash and cash equivalents were approximately RMB 299 million as of December 31, 2025, down from RMB 340 million in 2024[6]. - The group’s total liabilities decreased to approximately RMB 95.6 million as of December 31, 2025, from RMB 114.2 million in 2024[6]. - Total assets decreased to RMB 421,730,000 in 2025 from RMB 468,964,000 in 2024, reflecting a decline of 10.1%[27]. - Total liabilities decreased to RMB 97,630,000 in 2025 from RMB 117,358,000 in 2024, a reduction of 16.8%[27]. - Trade receivables decreased to RMB 3,678,000 in 2025 from RMB 9,561,000 in 2024, with a provision for losses of RMB 118,000 in 2025[42]. - The company’s total other receivables decreased to RMB 2,901,000 in 2025 from RMB 3,190,000 in 2024[42]. - Interest payable as of December 31, 2025, included RMB 4,676,000 related to convertible bonds, compared to RMB 3,100,000 in 2024[47]. Segment Performance - For the fiscal year ending December 31, 2025, the reported revenue from external customers for the pharmaceutical products segment was RMB 85,900,000, with an adjusted EBITDA loss of RMB (7,261,000)[16]. - The pharmaceutical products business incurred a loss of RMB 72.6 million during the reporting period, a decline from a profit of RMB 36.8 million in the previous year[62]. - The financing leasing business generated zero revenue during the reporting period, down from RMB 1.7 million in the previous year, due to the expiration of most existing contracts[63]. - The acquisition of a 51% stake in Beijing Hangyang Health Technology Co., Ltd. in May 2024 contributed approximately 68.12% to the total revenue of the pharmaceutical products business[61]. Expenses and Costs - Distribution costs for the year ended December 31, 2025, were approximately RMB 86 million, an increase of about RMB 23.5 million from RMB 62.5 million in 2024[73]. - Administrative expenses for the year ended December 31, 2025, were approximately RMB 287 million, an increase of about RMB 26.5 million from RMB 260 million in 2024[74]. - Financial costs for the year ended December 31, 2025, were approximately RMB 28.2 million, compared to RMB 22 million in 2024, mainly due to interest expenses from borrowings[76]. - Employee costs for continuing operations rose to RMB 23,199,000 in 2025 from RMB 19,509,000 in 2024, an increase of 18.0%[30]. - Research and development expenses increased to RMB 2,754,000 in 2025 from RMB 1,710,000 in 2024, an increase of 60.9%[30]. Corporate Governance and Compliance - The company is committed to high standards of corporate governance, ensuring the protection of shareholders' interests and long-term development[109]. - All directors confirmed compliance with the standard code of conduct for securities trading during the reporting period[111]. - The audit committee, consisting of three independent non-executive directors, reviewed the financial reporting procedures and internal controls, ensuring compliance with relevant accounting standards[114]. - The company confirmed that it maintains sufficient public float as required by listing rules during the reporting period[116]. Capital Management - The company plans to implement a capital restructuring involving a share consolidation and capital reduction, effective from August 13, 2024, and February 3, 2025, respectively[55]. - The total issued and paid-up capital as of December 31, 2025, was RMB 1,421,000, a decrease from RMB 35,534,000 in 2024[53]. - The company proposed a capital reduction by canceling HKD 0.24 of the paid-up capital per share, reducing the par value of each issued share from HKD 0.25 to HKD 0.01, and splitting unissued shares into 25 new shares of HKD 0.01 each[106]. Legal Matters - The company received a civil judgment from the Beijing Fourth Intermediate People's Court on December 22, 2020, regarding a lawsuit involving Fujian Sanai Pharmaceutical Co., Ltd., claiming unpaid lease payments totaling RMB 33,855,032.69 and other associated costs[99]. - The judgment required Fujian Sanai to pay a total of RMB 67,371,546.21 in principal, RMB 57,636,357.78 in overdue interest, and RMB 2,904,331.80 in penalties, with the company and its former directors jointly liable for these amounts[102]. - The company filed an appeal against the judgment on January 22, 2021, arguing that the financing lease agreement and guarantees were invalid[101].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因依賴該等內容 而引致的任何損失承擔任何責任。 本公司董事會（「董事會」）謹此知會本公司股東（「股東」）及本公司潛在投資者，根據 目前可得資料及對本集團截至二零二五年十二月三十一日止年度（「本期間」）的未經 審核管理賬目的初步審閱，預期本公司將錄得虧損介乎人民幣25.5百萬元至人民幣 27.5百萬元，而二零二四年同期則錄得溢利約人民幣3.4百萬元。 預期由二零二四年錄得溢利轉為二零二五年錄得虧損主要由於：(i)本公司於二零 二五年錄得出售附屬公司的虧損淨額約人民幣0.8百萬元，而於二零二四年同期 則錄得出售附屬公司的一次性非經常性收益淨額約人民幣 17.1百萬元；(ii)與二零 二四年同期相比，本公司於二零二五年錄得毛利減少約人民幣2.5百萬元，主要由 於中藥材成本持續上升，其增幅超過了本公司終端產品的售價升幅；及(iii)本公司 已於本期間入賬分銷成本及行政開支合共增加約人民幣5.0百萬元，主要歸因於北 京航洋健康科技有限公司及其附屬公司，而主要部分 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因依賴該等內容 而引致的任何損失承擔任何責任。 Sanai Health Industry Group Company Limited 三愛健康產業集團有限公司 執行董事 佘昊 香港，二零二六年三月十九日 （股份代號：1889） 董事會召開日期 本公告乃根據香港聯合交易所有限公司證券上市規則第13.43條刊發。 三愛健康產業集團有限公司（「本公司」）之董事會（「董事會」）欣然宣佈，本公司將於 二零二六年三月三十一日（星期二）舉行董事會會議，藉以（其中包括）考慮及批准本 公司及其附屬公司截至二零二五年十二月三十一日止財政年度之經審核財務業績及 考慮派付末期股息（如有）。 承董事會命 三愛健康產業集團有限公司 （於開曼群島註冊成立的有限公司） 於本公告日期，董事會包括三名執行董事，分別是袁朝陽先生、佘昊先生及謝海京先生；以及三名 獨立非執行董事，分別是朱依諄教授、許麒麟先生及徐婉丹女士。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 三愛健康産業集團有限公司 呈交日期: 2026年3月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01889 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 HKD | | | 100,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 HKD | | | 100,000,000 | 本月底法 ...

Group 1 - The Wanjiacn Central State-Owned Enterprises Dividend ETF (159333) closed at a 2.49% increase with a trading volume of 28.82 million yuan on February 24 [1] - The fund was established on August 21, 2024, with an annual management fee of 0.50% and a custody fee of 0.10% [1] - As of February 13, 2025, the fund had 333 million shares and a total size of 486 million yuan, showing a decrease of 15.91% in shares and 13.21% in size compared to December 31, 2025 [1] Group 2 - The current fund manager is Yang Kun, who has managed the fund since its inception, achieving a return of 48.41% during his tenure [2] - The latest report indicates that the top holdings include COSCO Shipping Holdings, China Shenhua Energy, CNOOC, Sinopec Engineering, China National Shipping, CITIC International, PetroChina, China Coal Energy, and China Construction Bank, with respective holding percentages [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 三愛健康産業集團有限公司 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01889 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | 本月底法 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 三愛健康産業集團有限公司 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01889 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | 本月底 ...

Fund Allocation - The company plans to allocate approximately 45% of the net proceeds from the issuance of convertible bonds for the purchase of production facilities, equipment, and raw materials for pharmaceutical products [2]. - About 30% of the net proceeds will be used to enrich the pharmaceutical product base, including the development of new drugs and/or obtaining drug licenses [2]. - Approximately 25% of the net proceeds will be allocated to increase sales points and additional sales personnel costs [2].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 三愛健康産業集團有限公司 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01889 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | 本月 ...

Core Viewpoint - Sanai Health Group (01889) has entered into a share transfer agreement to sell 99% of its equity in Luan Nan Hang Yang Health Industry Co., Ltd. for approximately RMB 18.69 million, which will be settled in cash [1][2] Group 1 - The seller, Beijing Hang Yang Health Technology Co., Ltd., a non-wholly owned subsidiary of the company, has agreed to sell its stake in the target company [1] - The target company, established in January 2018, has not commenced operations and holds a land parcel of approximately 67,000 square meters in Luan Nan, China [1] - The board believes that continuing to hold the stake may not yield the best returns for shareholders, and the sale is seen as an ideal opportunity to generate additional cash flow [1] Group 2 - The estimated net proceeds from the sale, after deducting related expenses, are approximately RMB 18.68 million, which the company plans to use for general working capital and other business development [2] - The completion of the sale is expected to improve the group's liquidity position and strengthen its financial status, allowing the company to focus on its core business [2]